Editor's note " Vertigo and moti on sickness . Part I: Vestibul ar anatomy and phy siology," appeared in the Sept emb er 2005 issue of ENT J OURNAL , pp. 581-4.
Introduction
Th e ef ficacy of medication s used to treat vertigo often can be inferred from their usefulness in treatin g motion sickness . Thi s is espe ciall y true when the medic ation bein g eva luated is a vestibular suppressant. Additional objective data co nce rning a dru g's efficacy can be gai ned from ( I) large clinica l studie s of patient s who exper ience similar environme ntal challenges, (2) evaluatio n of laboratoryinduce d motion sickness, (3) electronystag mog raphy, and (4) animal studies.
Clinical trials. Interest in studying treat ments for motion sickness increased du ring World War II whe n large numbers oftroo ps were being transported by sea.Transport From ENT Associates. Johnson ships provided a good setting for early studies comparing efficacy. Research co ntinued, and in a notably large study publi shed in 1980, Hargrea ves reported the result s of a doubl e-blind, placebo-controlled evaluation of cinnari zine for the prophylaxis of seas ickness.' In that study, 335 volunteers wer e given either cinn arizine or placeb o du ring voyages of 5 to 7 days. Symptom s were evaluated by questionn aire, and the result s indic ated a statistica lly significant redu ction in the incid en ce of sea sickness in the ac tive-trea tme nt gro up. Similar stud ies are still being perform ed .
Rotation testing. Probably the most w ide ly used meth od of objective ly eva luating an antivertiginous dru g's efficacy in the laboratory involves indu cin g moti on sicknes s in a co ntro lled fashion. Subj ects are placed in a chair and rotated about a ver tical ax is. Subje cts are then aske d to perform a defined series of head motion s out of the plane of motion over a set period of time. Th e numb er of head movem ent s that can be acco mplished before vomit ing or severe nausea occurs or prior to the subj ect's requ est to stop the rotati on becomes an obje ctive mea sure of toleran ce to motion sicknes s-inducing stimuli. Each subje ct can be used as his or her own control , which allow s researchers to indi vidualize the rate of rotation. More susce ptible subjects are then abl e to participate at a slower, more comfortabl e rotati onal veloc ity with out co mpro misi ng the integrit y of the study.' Caloric stimulation. Electronystagm ograph y can be used to test a dru g's ability to suppress ves tibular activity. In a study comparing the antihistamine d imenh ydrinate with placeb o, Barber et al exa mined cha nge s in the freque ncy, duration, and velocity of the slow componentofnystagmus.' Th ey found that measurement of the veloc ity of the slow co mponent was the most useful ind icator of suppres sed vestibular functio n.
Animal models. A numb er of anima l models for the study of motion sickness have been used over the years. Resea rchers once expressed some co nce rn about the use of canine models in early studies because dogs did not respond to scopo lamine, while hum ans experience a strong reaction; however, subsequent trials suggested that the problem with these ea rlier studies might hav e simply been inadequate dosing. Feline models are very useful becau se we hav e acc umulated a wealth of neuroanatomic, neuroc he mical, and neu roph ysiol ogi c informatio n on ca ts. Rat mo de ls are un iqu e in tha t these anima ls do not vomit in res po nse to co rio lis sti m ulatio n, but they do dem onstrate obse rva ble beh avior al cha nges such as pica (eating nonn utritive substa nces such as kaoli n). Rats are ge nerally easier to handl e than larger ani ma ls, and they require less stimulation time than do dogs and cats.' Sq uirre l mon keys are the on ly primates co mmo nly used in anima l studies of motion sick ness . Th ey are highl y susceptible to motion sickness indu ced by co riolis sti m ula tion, and thei r res po nse to anti-mo tion sickness dru gs is similar to that of hu man s.' In this artic le, we review the differe nt classes of drugs that are used to treat moti on sickness and vertigo. We discu ss the age nts that are now available (table I) and those that are still und er inves tiga tio n (table 2). (In part I of this article, we discu ssed the essential ana tomy and ph ysiology of the vest ibular sys te m and the associated vo miting re flex .")
Benzodiazepines
Diazepam. Sekit ani et al first reported on the suppressant ac tivity ofdiazepam in the me dia l ves tibu lar nuclei ofcats.' Th ey used microelectrod es to record the spo ntaneo us firing rates of neurons in the me dial ves tibular nucleu s. Th ey fo und that di azepam 0.4 mg/kg exerted stro ng suppressant ac tivity and red uced the firing fre quency by nearl y 75%.
Th ey also fo und that a dosage as low as 0 . 1 mg/kg had similar sup pressant act ivi ty. Both of the y-a minobutyric aci d (G ABA) recept ors-GAB A A and GABA B-have been found in the vesti bular nucle i, but ben zod iazepi nes are active only at the GAB A A receptors. Th ese receptors are bel ieved to med iate diazep am 's vestibular suppressant ac tivity.'
Diazepam has been tes ted spec ifica lly fo r the preventio n of motion sickness in hum an s. McClure et al alterna ted ora l ad ministratio n of diazepam 5 mg, dim enh ydr inate 50 mg, and placeb o in a gro up of normal subjects; subjects we re also tested afte r receivi ng no treatment.t Results were determi ned accordi ng to the length of time that had passed bet ween ad mi nistratio n and ex pos ure to moti on stimuli. Moti on stimuli were provided by rotatio n and head-tilt maneu vers, and treatment efficacy was measured by analyzing the number of maneu vers tolerated and the recordings of ski n sweat se nsors . Th e grea test effect was observed whe n patient s took diazep am or di me nhydri nate 120 minutes prior to the onset of the stimuli, whic h was the longest interval studie d. Clinicall y, doses of diazep am as sma ll as 2 mg ca n be effective in co ntro lling ver tigo.
Lorazepam. Intravenou s loraze pam is used to treat ac ute ves tibular vertigo in some eme rgency departm ents. Marill et al compared lorazep am 2 mg IV with dimenh yd rin ate 50 mg IV and fo und tha t lor azepam pro vided better co ntrol of sy mpto ms." 26 Clonazepam. C lo naze pa m, which has marked antiep ileptic properties, was rep orted to control sympto ms in most patient s in a study of migrain e-rel ated vertigo." Because the drug takes 4 hours to reac h peak plasm a levels, it is not used ora lly fo r ac ute ver tigo.
A lprazalam. The properties of alprazola m, a sho rtacti ng ben zod iazep ine, are simi lar to those of di azepam. However, short-ac ting be nzo diaze pines carry a greater risk for abuse and wi thdrawal sy mp toms . Ben zod iazep ines also have ge neralized ce ntra l nervou s system effects, and they are sedating.
Care should also be taken to avoid ben zodiazep ine ove rdose, which ca n result in res piratory depression , especially in elderly individu als.
Antihistamines
T he histamine-I (H I) blockers have long been used to prevent motion sic kness. It has been arg ued that their antivertiginou s efficacy is not the res ult of the HI effects but ra ther the res ult of thei r ce ntra l an ticho linerg ic ac tio ns. I I Wood et al co mpared antihistamines to ph en oth iazines, anticho linerg ics, sy mpa tho mime tics, and va rio us combinations." Subjects we re eva luated (I ) in a slow-ro tation roo m, (2) during aerobatic maneu vers, (3) at sea, and (4) during zero -gravity parab olic flight. Results were base d on the duration of stim ulus that was tolerated . Th e authors co ncl uded that antihis ta mines as a gro up are in the moderate ra nge ofeffectiveness for the treatm en t of mot ion sickness . Most of these age nts are suffic ient fortreating motion sickness indu ced by civ ilian travel, but antihistamines are not as usefu l in severe co nd itio ns or in highl y se nsi tive patie nts . (Co mbina tions of a sympatho mime tic and sco po lamine or pro me thazi ne were most effective.)
Ethanolamines . Two of the most studied anti-motion sick ness dru gs are dip hen hydra mi ne and dimenh ydr inate. Wood and Graybiel inclu ded these two me dicatio ns in thei r evaluation of the relative efficacy of 16 an timot ion sick ness drugs.' Thi s study involve d the laboratory assessme nt of human subjec ts who performed head-tilt maneu vers dur ing ro tation abo ut a ve rtica l axis. Efficacy was j udge d by the nu mber of head tilts that were tolerated. Dimenhyd rinate 50 mg proved to be more effective than meclizine 50 mg . In addi tio n, Muth et al fo und that dimenh ydrinate reduce d increases in gastric mo tility during mo tion sick ness-ind uc ing stimuli."
Ethylenediam ines and alkylamines. Et hy lenediamines (e.g., tripelenn am ine) have H Iantagonistic effects, but they do not demonstrate strong ce ntraleffects. Alkylam ines (e.g., chlorphenira mine) are effect ive at low doses in preventing moti on sickness, bu t they do have strong ce ntra l effec ts and therefore produce mar ked drowsiness.
Piperazines. Mecl izin e, cycliz ine, and bucl izine are longac ting antihis ta mi nes. T hey also produ ce light sedation . Meclizi ne, the bes t known of these, is commo nly used fo r 
Antiadrenergic and 1M/slow IV: drope ridol Hypotension, respiratory antidopaminerg ic effects; 2.5 to 5 mg/fe ntanyl dep ression; use w/caution analgesia w/fen tanyl 50 I-lg/ml q 12h in patients w/ liver or kidney disease ZAJONe, ROLAND Table 2 . Selected investigational medications and agen ts not approved in the U.S. the preve ntion of motion sickness in civ ilian environments.
Drug

Anticho line rgics
In addition to the finding that meclizine 50 mg was less effective tha n dimenhydrinate 50 mg, ? mecl izine has been found to be less effective tha n transdermal sco polamine. In a placebo-con tro lled study, Dahl et al exposed 36 subjects to a ship-motion simulator after they had rece ived either ora l meclizine 25 mg ora transdermal scopolamine patch. " 28 Mecl izine was given 2 hours prior to testing and transdermal scopolamine was given 12 hours prior to testing. Subjects were graded on a 5-poi nt nausea scale, with 0 representing no symptoms and 5 representing vomiting. Su bjects who wore the scopolam ine patc h had significantly lower scores than either the mecl izine or placebo subjects ; meclizine was sign ificant ly more effective than placebo. Cinnarizine is a piperazine that exerts calcium channel blocking effects. It has been used in Europe for many years, but there is concern regard ing its central side effects. (Cinnarizine is discussed in more detail in the section on "Ca lcium antagonists.") Piperidin es. The best known piperidine is terfenad ine. Although it has been removed from the market, one human study by Kohl et al demonstrated that a single large (300 mg) dose of terfenadine increased to a statistically significant degree the number of head movements tolerated by subjects during rotation .IS Because terfenadine does not cross the blood-brain barrier, this fi nding raised the possibility that motion sickness might be treatable by blocking only peripheral receptors. However, structures such as the area postrema, median eminence, portions of the hypothalamus, and other circu mventricular organs that lie outside the blood-brain barrier play an integral role in the vomiting reflex. Therefore the effectiveness ofterfenadine may well be attributable to its central sites of action.
Aste mizo le, another highl y selective HI inhibitor with little central nervous system penetration, has also been reported to be effective in the treatment of chronic vertigo. t'-'? In a prospective study, Jackson and Turner eval uated 38 patients with chronic vertigo who exhibited repeatable spontaneous or positional nystagmus.'? Patients with Meniere's disease were excluded from the study. Patients were given 5, 10, or 20 mg/day of astemizole for 13 weeks. Patients were evaluated by electronystagmography. A positive response was defined as a 50% reduction in the number of nystagmus beats recorded during a body-positioning protocol. Patients were also evaluated by a subjective symptom questionnaire. This study revealed that although some patients showed no objec tive or subjec tive changes, 73% did improve. Responses were demonstra ted after 2 to 4 weeks of therapy, and the return of symptoms was delayed by 2 weeks or more after the drug was discontinued.
In another human study, Kohl et al tested 20 subjec ts after they had taken oral astemizole 30 mg/day for I week." Although subjects were found to have therape utic blood levels of astemizole, the drug demonstrated no effectiveness against motion sickness-inducing stimuli. These subjects also exhibited no change in their vestibuloocular reflex.
Phenothiazin es. The phenothiazines were first explored for their usefulness in treating psychoses. They also have antiemetic properties, but most drugs in this grou p are only slightly effective against motion sickness, promet hazine being a notable exceptio n.
Promethazine exerts strong antihistamine propert ies, and it is more effective than any antihistamine in preventing vertigo. Promethazine also has the strongest anticholinergic activity of all the phenothiazines . Wood and Graybiel reported that oral promethazine 25 mg was only slightly less effective in preventing motion sickness than scopolamine Volume 85, Number 1 0.6 mg.' Intramuscular promethazine 25 mg was shown to increase the number ofh ead movements tolerated by 78%, although this was less than the 9 1% reductio n seen with scopolamine 0.2 mg." However, promethazine's duration of action is 12 hours, versus 4 hours for scopolamine. 19 Promethazine hastens adaptation to motion sicknessinducing stimuli, as Lackner and Graybiel demonstrated in a controlled human head-tilt experiment.20 Three groups of subjects were given either placebo or promethazine 50 mg orally prior to testing sessions. The sessions were held 2 days apart to allow for habituation. Patients in one of the two promethazine groups were allowed to perform as many head movements as possible, while those in the other promethazine group were forced to match the number of head movements performed by those in the placebo group. At the final session, all groups received placebo only.Analysis of the results revealed statistically significant increases in the number of head movements performed by all groups. However, the group given promethazine and allowed to perform as many head movements as possible showed the greatest improvement.The promethazine group inwhich the numberofhead movements was restricted did no better than the placebo group. These findings suggest that if subjec ts increase theirexposure to motion sickness-inducingstimuli, promethazine may actually help to increase adaptation.
Promethazine does exert significant sedating properties and the 25-mg dose can impair functional performance, but the sedative effect can be circumve nted by adding 10 mg of amphetamine/dextroamphetamine (d-amphetamine). Larger doses of promethazine degrade performance to such an extent that sedation cannot be prevented by adding amphetamine." (As discussed later in this article, d-amphetamine exerts antivertiginous effects of its own.)
Prochlorperazine, another phenothiazi ne, demonstrates HIblockade and it has significant anticholinergic properties. It also has a 40-fold greater antidopaminergic effect than does promethazine, and it is an effective antiemetic. Prochlorperazine does have some anti-motion sickness effects, but it ranks well below scopolamine and the antihistamines in this regard. For examp le, not only was prochlorperazi ne 5 mg shown to be less effective than meclizine in preventing motion sickness, tripling the dose actually decreased the number of head tilts tolerated."
Chlorpromazine has no anti-motion sickness efficacy, even though it isquite effective against chemically induced nausea."
Anticholinergics
Anticholinergic medications act on muscarinic receptors. (There are five known structural subtypes of muscarinic receptors, designated m l through m s' The capitalized designations M I, M 2 , and M) represent pharmacologic definitions, which are based on the actions of various drugs that bind muscarinic receptors selectively.) One study involving bovine brain tissue found that the highest densities of muscarinic receptors were in the area postrema and the vagal nuclear complex ." Intermediate densities were found in the parvicellular reticular formation, and the lowest concentration of receptors was found in the vestibular nuclei.
Scopolamine. Scopolamine is believed to bind well to all types of muscarinic receptors . In their study of 16 agents, Wood and Graybiel found that oral scopolamine was the most effective single agent in preventing vertigo .' They also evaluated scopolamine in combination with two other adrenergic medications that were found to have antimotion sickness activity of their own; scopolamine had an additive effect when combined with ephedrine and a synergistic effect when combined with amphetamine.' In fact, the combination of scopolamine and amphetamine proved to be the most effective of all medications alone or in combination. Operational performance has been shown to decrease with doses of scopolamine of 0.8 mg or more. However, the addition of d-amphetamine 5 mg with scopolamine 1.0 mg prevented a decrease in performance."
Although scopolamine is effective, adaptation to new environmental stimuli can be delayed. This was demonstrated in one clinical study of 51 sailors who worked in rough seas over a period of7 days." Upon embarking on their voyage, the subjects were given either transdermal scopolamine or transdermal placebo and instructed to wear the patch for 3 days . Initially, vomiting did occur less often in the scopolamine group. But on day 6, 3 days after removal of all patches, vomiting occurred in 23% of the scopolamine group but in none of the placebo controls.
The scopolamine transdermal therapeutic system delivers a continuous I-mg total dose over 3 days; thereafter, a new patch may be applied. The effectiveness of transdermal scopolamine has been proven to be similar to that of oral scopolamine." Its autonomic side effects include reduced salivation and blurred vision from reduced accommodation. The most common side effect is dry mouth , which has been reported in 30 to 50% of patients. Blurred vision commonly occurs with continued use . In a study of 12 subjects, Parrot monitored visual acuity during the placement of sequential patches." Blurred vision occurred in I subject upon placement of a second patch, 4 subjects experienced blurred vision with a third patch , and 6 reported blurred vision with a fourth. Central nervous system side effects include decreased alertness, impaired attention , and difficulty remembering new information.Addiction and psychosis have also been reported with the use of trans dermal scopolamine for I month or longer.25.27.28 Reports of addiction relate to patients' inability to discontinue medication because of severe withdrawal symptoms, such as nausea , vomiting, headache, and disequilibrium.28 Transdermal scopolamine has also been documented to cau se acute angle-closure glaucoma, and therefore it should not be used in patients 30 suspected of having glaucoma." Contact dermatitis may occur in 10% of patients after I month or more of use; this rate may rise to more than 30% among patients who use transdermal scopolamine for I year or longer,"
Buccal administration of I mg of scopolamine in a sustained-release hydroxypropylmethylcellulose vehicle was shown to reduce vomiting during parabolic flights by 50 % and to reduce nausea scores by approximately 31%.3 1
Glycopyrrolate. Glycopyrrolate is commonly used to decrease copious secretions and to prevent traction-induced vagal inhibitory cardiac reflexes. Storper et al tested glycopyrrolate for efficacy in treating vertigo in 37 patients with Meniere's disease." Of this group, 22 patients were given oral glycopyrrolate 2 mg twice a day. Compared with the remaining 15 patients who had not received glycopyrrolate, the study group had a significantly greaterreduction in Dizziness Handicap Inventory scores.
Idaverine. Idaverine, which is not approved in the United States, is believed to be a selective M , and M 2 antagonist with a significantly lower affinity for M 3 receptors. Lucot et al investigated its efficacy in preventing motion sickness by comparing it with scopolamine in a cat model." They found that idaverine exerted no protective effects; in fact, larger doses actually induced emesis. This finding suggests that the M 3 receptor may be responsible for the anti-motion sickness effects of scopolamine.
Zamifenacin. Zamifenacin is a new selective anticholinergic under investigation. This agent binds selectively to M 3 and m 5 receptor subtypes, and it has been shown to be as efficacious as scopolamine in preventing motion sickness." This suggests that the M 3 receptor, the m 5 receptor, or both may be responsible for scopolamine's anti-motion sickness effect. Further research mayor may not determine that the use of zamifenacin or other selecti ve anticholinergics can effectively control motion sickness and vertigo with fewer side effects .
Neuroleptics
Neuroleptics are known for their antipsychotic properties. Two major groups of neuroleptics are the phenothiazines and the butyrophenones. (The phenothiazines are discussed in more detail in the earlier section on "Antihistamines. ")
The butyrophenones are essentially derivatives of haloperidol. Droperidol is used almost exclusively in anesthesia because of its strong sedating properties and antiemetic effects. Droperidol has antiadrenergic and antidopaminergic effects. It is believed that its antinausea effects may be attributable to the blocking of dopamine receptors in the area postrema. A fixed-dose combination of droperidol2.5 mg/ml and fentanyl 50 ug/ml is commercially available. Droperidol has bee n prove n useful , either alone or in com binatio n with fentany l, in clinical studies of trea tme nts for acute ve rtiginous ep isodes brought on by Me niere's disease.v -" Gates reported his personal experie nce with droperid ol/ fent an yl for the co ntro l of verti go in 12 patient s with Men iere 's disease." He found that 58 % of these patient s achieve d long-term cont rol of their vertigo during a follow -up of 2 to 8 yea rs. Th e mechani sm for any proposed lon g-term effec ts of dro perido l/fe ntanyl is not clear. Cu rren tly, droperidol/fent an yl is bein g used in emerge ncy departm ent s for the co ntro l of acute peripheral ve rtigo ; goo d result s have been reported by Irvin g et aJ. 38 John son et al eva luated droperidol alone for the co ntro l of peripheral ver tigo." Twelve patients with ac ute ver tigo seco ndary to Men iere 's disease were given either placebo or drop eridol5 mg intramusc ularly. Patient s in the activetreatment gro up experienced a reso lution of symptoms within 60 minutes, where as the co ntrols remai ned unchanged . Th e co ntro ls were then put on droperidol , and their ver tigo reso lved, as we ll. Th e usual dro perido l dose for adults is 2.5 to 5 mg intramuscul arl y or intraven ously. Monitorin g of vital signs and respiratory support are necessary du ring administration in view of the dru g's risk for caus ing hypotension and respiratory de press ion. Ben adryl 25 to 50 mg ca n also be give n prior to dro per ido l administration to he lp prevent ex trapyra midal side effects."
A highl y selective dopami ne-2 (D2) receptor antago nist, I-sulp iride, is und er inves tiga tion. In squirre l monkeys, I-sulp iride has been found to exe rt stro ng an ti-motion sic kness effec ts and no extrapyra mida l side effec ts at the dosing levels studie d. Mi ller and Brizzee co mpared l-sulpi ride with do mperido ne, a peripherall y ac ting D 2 antago nist." Domperidone dem onstrat ed no ability to prevent mot ion sick ness . Because domp eridone wo uld have been avai lable to the area postrem a (outside the blood-brain barrier), it is likely that the anti-motion sic kness effects of l-sulpi ride occ ur outside the area pos trema. This co njec ture supports the hypoth esis that although the area postrem a is part of the chemo rece ptor trigger zo ne, it is not assoc iated with the production and co ntro l of moti on sick ness .
Anticonvulsants
Phen ytoin acts diffusely upon the ce ntra l nervous system to stabilize neu ronal membranes. It is believed to stabilize the threshold aga inst hyperexcit abil ity ca use d by excessive stimulation while leaving normal neur onal activity esse ntia lly unaffecte d.v-" The ne ura l mism atch produced by moti on sic kness ca n be viewe d as a so urce of excessive stimulation. Chelen et al investigat ed the usefuln ess of phen ytoin in preventing motion sic kness in 7 health y male volunteers using a rota tion and head-tilt protocol." Subjects were treated with a loadin g dose of I to 1.4 gra ms of phen ytoin dur ing the 20 hours preced ing the study, and their blood was tested to measur e therapeuti c levels. Th e authors discovered that phenytoin was associated wit h an II-fold longer dura tion of to lerance to exposure than placebo. T his duration of tolerance was 4-fold grea ter than that associated with a sco polamine/ d-amphetarnine combinati on . Ch elen et al made no specific recommend ation to use phen ytoin to prevent moti on sick ness, but they alluded to larger ongoi ng trials that they were co nduct ing. In another study, Stern et al showed that phenyto in decreased gas tric mot ility in response to motion sickness -inducing stimuli."
Calcium antagonists
Calcium ions are prese nt in the endo lymph. In respo nse to movemen t of the endo lymph, calcium ions flow into the ce lls of the cri sta ampullaris. Th is triggers an action potenti al that is propa gated ce ntra lly. It is postul ated that ca lcium cha nnel blockers inhib it the flow of ca lcium fro m the endo lymp h into the ce lls of the crista amp ullaris."
Flunarizin e, Flun arizine is one ca lcium cha nnel blocker that has been found to be a power ful periph erall y acting labyrinth suppress ant. At both 10 and 30 mg, it has been found to be more effective in reducing ca loric responses than is proc hlorperazi ne 5 mg." Add itio nally, flunariz ine reduces ves tibulooc ular reflex gain in harmonic acceleration tests, and it is clinically useful in preventing motion sickness and vertigo.v-"
Cinnarizine. Cinnarizine is similar to flunarizin e, but it is less po tent. Th e usual dose of cinnarizi ne is 30 mg ora lly 2 hours prior to motion sickness-induci ng stimuli.
Durin g prolonged ex pos ure to stimuli , cinnarizine can be continued at 15 mg three times dail y. Children age d 5 to 12 years ca n be treat ed wit h one-ha lf the adult dose. In a slow-ro tation study, cinnarizine was show n to increase the num ber of rotations tolerated before the developm ent of motion sick ness." Cinnarizine has also been proven effective in placeb o-controlled studies of seasickness.':" In a study of saccadic eye movem ent s afte r inges tio n of either flunar izine or cinnarizi ne in 10 subjec ts, Sh upak et al fou nd that peak saccadic velocity was sig nifican tly lower in the flunari zine group.' ? (Saccadic veloci ty is relat ed to a gro up of bur st neurons in the brain stern.) Th e 32 subjects who took cinna rizi ne de mons trated only a trend toward redu ction in peak saccadic veloci ty. Thi s finding sugges ts the possibility that ca lcium antagoni sts exert ce ntra l effec ts.
Flun arizine and ci nnar izine have been used in Europe, but not wide ly elsew here in the wo rld. Nei ther drug is selective for a particul ar calc ium cha nnel subtype . They therefore exer t their effe cts throughout the central nervous system. Potenti al side effects include weight gain, depression, sedation, and eve n parki nso nian sy mptoms. Flu narizine has a long half-life, and steady -state plasma levels are not reac hed for 2 month s. Residu al co ncentrations are detectable for up to 4 month s after cessa tion of therapy.v -":" Nimodipin e. Ni mod ipine is a highl y lipoph ilic age nt that read ily crosses the blood-p er ilym ph barrier. It is approve d in the U.S. fort he redu ction of cere brovasospas rn followi ng subarachno id hem orrhage. In a retro specti ve study, Lassen et al report ed that nim odipine was given to 12pati ent s with Meniere 's disease who had fai led to res pond to first-line medi cal managem ent with diet restriction s and a diuretic (and, on occasion, a vesti bular suppressant)." Th e authors found that ve rtigo had been co ntrolled in 67% of these patien ts. Th e duration of treatm ent and foll ow-up in this study ranged from 5 to 27 month s; patien ts who had failed treatmen t did so within 6 month s. In ad dition to blocking calcium influx into ves tibular hair ce lls, nimodipi ne's anti vertiginous effects might be attributable to its ce ntral modul ation of signals seco nda ry to peripheral ves tibular irritation. The reco mme nded dosage for nimodipin e is 30 mg twice a day. 39.52 Nifedipine. During a do uble-b lind study of nifed ipine 's antihypertensive effects, Marley and Joy sere ndipitously discovered that nifedipine allev iated a single patient 's motion sic kness."
Sympathomimetics
The anti-motion sick ness efficacy of d-amphetamin e alone was found to be equal to the midrange efficacy of the antihistamin es in the co mparison study by Wood and Graybiel. 2 In a squirre l mon key study, d-amphetamine was also effec tive aga inst motion sick ness whe n the anima ls were exposed to a co mbinatio n of ve rtica l osc illations and horizont al rotation.' Th e mechani sm of action of amphetamine, a noradr en alin e releaser, in preventi ng motion sickness is unclear. Its effects were once be lieved to be produced by an increase in noradrenergic activity in the brainstem, but this hypoth esis is now being questi oned. Th is theory was weak ened by the res ults of an anima l study in which Takeda et al measured the turn over of catec ho lamines in rat brainstems during a double-rotation pro toco l; although meth amph etam ine 5 mg/kg preve nted pica, no increase in brain stem ca tec ho lamines was obse rve d."
An oth er theor y hold s that the anti-motion sickness ef- fects of amphetamine are attributable to the enhance ment of se lective dop amin ergic stimulation." Thi s hyp oth esis is supported by the fact that both meth ylph enid ate (a nonamphetamine-like stimulant that enhances dop aminergic transmi ssion but not norepinephrine transmi ssion) and d-amphetamin e have anti -motion sickness effects. The se dru gs may exert their anti-motion sickness effects via their si milar enhance me nt of dopamin ergic tran smi ssio n. 55 • s6 Additionally, the anti-motion sickness effects of the I-isom er of d-amphetami ne are weak er than tho se of d-amphetamine; the weaker do paminergic effec ts of the I-isom er might ex plain its lack of efficacy.P :" Eph ed rine 25 mg in combi nation with sco po lami ne ca n be used to lessen the performance degradation cause d by seda tion. Use of this combination also takes advantage of the synergis tic activity of the two medication s. Ephedrine 25 mg can also be used in combination with promethazine 25 to 50 mg.
Tricyclic antidepressants
Two of the tric yclic antidepress ants that hav e been inve stigated for anti-motion sickness effe cts are imipramin e and doxepin . (Ow ing to its ability to inh ibit seroto nin uptake , imip ramine is discu ssed later in the section on " New horizo ns" in the subsection on "Se rotonergic agoni sts and antagonists.") Doxepin exe rts strong HI ant agonistic effec ts, and it has ad rene rgic and anticholin ergic effects, as well. One hum an study demonstrated that doxepin is as effecti ve as the combination of scopolami ne and amphetamin e for the prevention of moti on sickness." Subjects were expo sed to rot ation with head-tilt man eu vers dail y for 5 con secutive days. Result s were based on the number of head tilts that wer e tolerat ed . Both treatment groups dem on strated incr easin g tolerance to coriolis stimulation daily (no statistic ally significa nt differenc e), suggesting that therap y fac ilitated adaptat ion, and both regim ens were significantly superior to placebo . However, doxepin does have substantia l seda ting prop ertie s as well as other und esirabl e anticholinergic side effects. Do xepin also has a strong potential for adve rse interactions with other dru gs. Biver et al studied the distribution of 5-HT 2 recept ors in hum an brain tissue via positron-emi ssion tornography .?' A rad iotracer speci fic for 5-HT 2 recept ors revealed a prim arily cortical distribution; these receptors were found to a lesser ex tent in the basal ga nglia and ce rebellum. A 5-HT2 agoni st-I-(2,5-d imethoxy-4-iodophen yl)-2-aminop ropan e (DOI)-has been shown to block emes is induced by mo tion and cis platin in an anima l mod el. 6s . 66 The 5-HT 3 receptors are present in high densities in both the ce ntral and peripheral ner vou s systems. Th ey are found in the area postrema , nucleus of the tractu s so litari us, cerebra l cortex, spinal cord, and visce ral autonomic and senso ry nerv es."? Th e 5-HT 3 receptor anta gonists (e.g. , ondansetron) are used extensive ly for the control of postoperativ e nausea and vomiting . Stott et al demonstr ated that their antinausea effect does not prevent motion-induced vomiting."
New horizons
Select ive serotonin reuptake inhibitor s (SSRIs) wor k by increasing synaptic conc entrat ion s of serotonin. Imipramine (a tricyclic antid epre ssant with stro ng serotonergic properties) and f1uox etin e (an SSRI) have been tested in the animal model SlIllClIS murinus/" Both age nts ex hibited dose-d epend ent effectiv eness in preventing motion sickness. T he ir usefuln ess in humans is not yet clear.
Neurokinin receptors. Neurokinin type I (NK) receptors are natu rall y bound by substa nce P, and they are involved in a variety of processes, including smoo th muscle re laxation or contraction, neuronal depol arizati on, and exoc rine gland sec retion. Sub stance P is a peptide neu rotransmitter that is locali zed to man y neu ron al structures . Sub stan ce P is believed to playa role in the tran smi ssion of sens ory infor mation, particul arly that associated with noxious stimuli, from the periphery to cent ral struc tures . Some NK 1 receptor antagoni sts have been shown to have strong antiemetic prop erties. One of the most selec tive NK I recept or antag onists, GR203040, has dem on strat ed effec tive ness aga inst motion-induced em esis in animal models." It should be noted that although thi s dru g is highl y selective for NK I recept ors, it has some affinity for H, receptors." In hum an studies, how ever, NK, rece ptor antago nists alon e and in combination with the 5-HT J recept or anta goni st ond ansetron have prov en to be no mo re effectiv e than placebo in the treatment of motion-induced nausea in hu mans." Th e fact that NK 1 rece ptor anta goni sts have dem onstrated effectiveness in prevent ing chemotherapyindu ced nausea but not motion sickness -induced nausea sugg ests that there is a different mechan ism of action for motion-induc ed nausea.
Misc ellaneous agents. N-m ethyl-D-asp artate (NM DA)
antago nists have been eva luated in anima l models in an effo rt to find a drug that will serve as a broad-spectrum ant iemetic.The selective co mpetitive ant agoni st LY233053 has been shown to act in this capacity by blocking both motion-and chemical-induced eme sis in cats." The sites of action appear to be both the vestibul ar nuclei and later in the final common pathw ay for vomiting.
Animal studies have also shown that short adrenocorticotrophic hormone (ACTH ) fragments relieve verti go symptoms and accelerate their disappearance.t -' -" The site of action of one fragment, ORG 2766, appears to be in the vestibular nucleus complex itself.
Ineffecti ve agents include ginger root and acety lleucine. Ginger root (Zingiber officinale) has been found to have no effect on motion sickness in rotary -chair tests and only a very mild effect on tachygastria in motion sickness." Acetylleucine, which has been used in France since 1957, has no clin ical trials to support its use; neither doe s the Ginkgo biloba extract EGb 761. 5 1
Selecting a medication
It is possible to pred ict the clinical usefulness of some medications by referring to the neurophysiologic model for vertigo and motion sickness. For example, if a vestibular suppressant is successful fortreating motion sickness, it will likely be useful fortreating vertig o, as well. It is also imp ortant to consider a medic ation 's onset of action . A drug with a rapid onset of action is requi red to treat acute vestibul ar vertigo orongoing motion sickness, where as a slow-acting medication is appropriate for chron ic vertigo.
